European heart journal. Case reportsOct 15, 2026

Heart rhythm problem improving after weight-loss drug semaglutide started in a resistant case of irregular heartbeat

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 16, 2026

Abstract

Obesity is a major modifiable risk factor for atrial fibrillation (AF).

Atrial fibrillation is associated with atrial structural and electrical remodeling linked to obesity.
Glucagon-like peptide-1 (GLP-1) receptor agonists may reduce cardiovascular events in high-risk patients with type 2 diabetes.
The impact of GLP-1 receptor agonists on atrial cardiomyopathy and direct antiarrhythmic effects is currently under investigation.

Simplified

Obesity is a major modifiable risk factor for atrial fibrillation (AF) and has been linked to processes involved in atrial structural and electrical remodelling. Glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular events in patients with type 2 diabetes at high cardiovascular risk and are increasingly regarded as cardiometabolic therapies. Whether these agents modify the trajectory of atrial cardiomyopathy or exert direct antiarrhythmic effects beyond their metabolic actions remains an area of active investigation.

Full Text

Full text is available at the source.

View Full Text ↗

Heart rhythm problem improving after weight-loss drug semaglutide started in a resistant case of irregular heartbeat

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief